Stock Events

Stock Events

Hillstream BioPharma 

$0.2370
37
+$0.01+5.66% Friday 21:59

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
2.73M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

29NovExpected
Q2 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q2 2023
Q3 2023
-0.18
-0.05
0.09
0.22
Expected EPS
-0.05
Actual EPS
0

Financials

-Profit Margin
Unprofitable
2020
2021
2022
0Revenue
-8.47MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap79.4B
Moderna, Inc. is a competitor because it also focuses on mRNA-based therapies, potentially overlapping with Tharimmune's immunotherapy approaches.
BioNTech
BNTX
Mkt Cap24.75B
BioNTech SE operates in the field of mRNA technology for developing vaccines and therapeutics, directly competing with Tharimmune's technology platform.
Novavax
NVAX
Mkt Cap1.75B
Novavax, Inc. competes in the vaccine development space, particularly in the development of vaccines for infectious diseases, which may overlap with Tharimmune's focus areas.
Pfizer
PFE
Mkt Cap163.41B
Pfizer Inc. has a broad portfolio in vaccines and biopharmaceuticals, making it a competitor in various therapeutic areas that Tharimmune may target.
Gilead Sciences
GILD
Mkt Cap187.15B
Gilead Sciences, Inc. is involved in the development of antiviral drugs and other treatments that could compete with Tharimmune's immunotherapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.13B
Regeneron Pharmaceuticals, Inc. is known for its work in immunology and infectious diseases, areas that Tharimmune may also be exploring.
Astrazeneca
AZN
Mkt Cap258.35B
AstraZeneca PLC has a diverse biopharmaceutical portfolio, including treatments for cancer and other diseases, potentially competing with Tharimmune's research and development.
Johnson & Johnson
JNJ
Mkt Cap653.61B
Johnson & Johnson operates in various healthcare sectors, including pharmaceuticals with a focus on immunology, making it a competitor to Tharimmune.
Merck
MRK
Mkt Cap367.07B
Merck & Co., Inc. has a strong presence in the development of vaccines and cancer therapies, areas that may intersect with Tharimmune's interests.
Sanofi
SNY
Mkt Cap98.51B
Sanofi is involved in the development of vaccines and treatments for immune system diseases, competing with Tharimmune in the immunotherapy space.

About

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.
Show more...
CEO
Mark Wendland
Employees
12
Country
United States
ISIN
US4327051011

Listings

MX
MX
CNTN.MX
BOATS
BOATS
THAR.BOATS
XNAS
US
CNTN

0 Comments

Share your thoughts

FAQ

What is Hillstream BioPharma stock price today?▼
The current price of HILS is $0.24 USD — it has increased by +5.66% in the past 24 hours. Watch Hillstream BioPharma stock price performance more closely on the chart.
What is Hillstream BioPharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Hillstream BioPharma stocks are traded under the ticker HILS.
What is Hillstream BioPharma market cap?▼
Today Hillstream BioPharma has the market capitalization of 2.73M
What were Hillstream BioPharma earnings last quarter?▼
HILS earnings for the last quarter are 0 USD per share, whereas the estimation was -0.05 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Hillstream BioPharma revenue for the last year?▼
Hillstream BioPharma revenue for the last year amounts to 0 USD.
What is Hillstream BioPharma net income for the last year?▼
HILS net income for the last year is -8.47M USD.
How many employees does Hillstream BioPharma have?▼
As of October 01, 2026, the company has 12 employees.
In which sector is Hillstream BioPharma located?▼
Hillstream BioPharma operates in the Health & Wellness sector.
When did Hillstream BioPharma complete a stock split?▼
Hillstream BioPharma has not had any recent stock splits.
Where is Hillstream BioPharma headquartered?▼
Hillstream BioPharma is headquartered in NEW YORK, United States.